JP2011504501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504501A5 JP2011504501A5 JP2010534969A JP2010534969A JP2011504501A5 JP 2011504501 A5 JP2011504501 A5 JP 2011504501A5 JP 2010534969 A JP2010534969 A JP 2010534969A JP 2010534969 A JP2010534969 A JP 2010534969A JP 2011504501 A5 JP2011504501 A5 JP 2011504501A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- cdr sequences
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 107
- 239000012634 fragment Substances 0.000 claims 26
- 101100366217 Gallus gallus SOSTDC1 gene Proteins 0.000 claims 15
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 101000825071 Homo sapiens Sclerostin domain-containing protein 1 Proteins 0.000 claims 4
- 102000057897 human SOSTDC1 Human genes 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000001474 proteinuria Diseases 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 102000004264 Osteopontin Human genes 0.000 claims 2
- 108010081689 Osteopontin Proteins 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 238000000423 cell based assay Methods 0.000 claims 2
- 230000037319 collagen production Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 238000013424 sirius red staining Methods 0.000 claims 2
- 208000037816 tissue injury Diseases 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 102100027211 Albumin Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102100029880 Glycodelin Human genes 0.000 claims 1
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US403707P | 2007-11-21 | 2007-11-21 | |
| US61/004,037 | 2007-11-21 | ||
| PCT/US2008/012987 WO2009070243A2 (en) | 2007-11-21 | 2008-11-21 | Wise binding agents and epitopes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014061293A Division JP2014167002A (ja) | 2007-11-21 | 2014-03-25 | Wise結合抗体及びエピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504501A JP2011504501A (ja) | 2011-02-10 |
| JP2011504501A5 true JP2011504501A5 (cg-RX-API-DMAC7.html) | 2012-01-12 |
| JP5583591B2 JP5583591B2 (ja) | 2014-09-03 |
Family
ID=40524859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534969A Expired - Fee Related JP5583591B2 (ja) | 2007-11-21 | 2008-11-21 | Wise結合抗体及びエピトープ |
| JP2014061293A Withdrawn JP2014167002A (ja) | 2007-11-21 | 2014-03-25 | Wise結合抗体及びエピトープ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014061293A Withdrawn JP2014167002A (ja) | 2007-11-21 | 2014-03-25 | Wise結合抗体及びエピトープ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8043620B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2220118A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5583591B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100099193A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101925611A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008330125B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0820387A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2705879A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO6311002A2 (cg-RX-API-DMAC7.html) |
| CR (1) | CR11523A (cg-RX-API-DMAC7.html) |
| EA (1) | EA201000844A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL205569A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA31918B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010005656A (cg-RX-API-DMAC7.html) |
| TN (1) | TN2010000213A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009070243A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201003578B (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| JP5574711B2 (ja) | 2007-02-09 | 2014-08-20 | アクセルロン ファーマ, インコーポレイテッド | 癌患者における骨成長を促進するためのアクチビン−actriiaアンタゴニストおよびその使用 |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ, インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用 |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| EP2507381A4 (en) * | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS |
| WO2011075636A2 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Wise binding agents and epitopes |
| BR112012021941A2 (pt) * | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| AU2012327223A1 (en) | 2011-11-30 | 2013-06-20 | Wellstat Diagnostics, Llc. | Assays, antibodies, immunogens and compositions related to 5-FU |
| WO2013103800A1 (en) * | 2012-01-06 | 2013-07-11 | Bioalliance C.V. | Anti-transferrin receptor antibodies and methods using same |
| FR2987293B1 (fr) * | 2012-02-27 | 2014-03-07 | Michelin & Cie | Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees |
| EP2904015A4 (en) | 2012-10-02 | 2016-10-05 | Univ Rutgers | TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| BR112015010360A8 (pt) | 2012-11-08 | 2018-01-16 | Eleven Biotherapeutics Inc | antagonistas de il-6 e utilização dos mesmos. |
| US20140171356A1 (en) * | 2012-12-12 | 2014-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically immobilized wnt protein and methods of use |
| AU2014315081A1 (en) | 2013-09-05 | 2016-03-24 | Duke University | Nav1.7 antibodies and methods of using the same |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| UA122673C2 (uk) | 2014-11-07 | 2020-12-28 | Елевен Байотерапьютікс, Інк. | Антитіло, що специфічно зв'язується з людським il-6 |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ActRIIアンタゴニスト及び貧血を治療するための使用 |
| JP2019510078A (ja) | 2016-02-23 | 2019-04-11 | セセン バイオ, インコーポレイテッド | Il−6アンタゴニスト製剤およびその使用 |
| CA3017958C (en) | 2016-03-18 | 2024-03-12 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
| EP3448875A4 (en) * | 2016-04-29 | 2020-04-08 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018129248A1 (en) * | 2017-01-06 | 2018-07-12 | The Regents Of The University Of California | Therapeutic anti-ige antibodies and methods and compositions thereof |
| US11021540B2 (en) * | 2017-09-07 | 2021-06-01 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| KR20220034176A (ko) * | 2019-07-12 | 2022-03-17 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체 |
| CN112180099B (zh) * | 2020-09-15 | 2022-07-29 | 江南大学附属医院 | 子宫内膜异位症血清标志物的应用 |
| IL314524A (en) | 2022-01-28 | 2024-09-01 | Georgiamune Inc | Antibodies to programmed cell death protein 1 that are agonists for PD-1 |
| CN115322258B (zh) * | 2022-05-31 | 2024-08-13 | 武汉真福医药股份有限公司 | 一种单克隆抗体qkma-1g41及其应用 |
| CN115304677B (zh) * | 2022-06-19 | 2024-08-16 | 湖北真福医药有限公司 | 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用 |
| CN116712533B (zh) * | 2023-07-03 | 2024-02-02 | 广东暨安特博生物科技有限公司 | 一种sostdc1蛋白在制备治疗皮肤病产品中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220912A1 (en) * | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| AU2003276430A1 (en) * | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| MXPA06010887A (es) * | 2004-03-23 | 2007-03-08 | Amgen Inc | Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano. |
| PL3345607T3 (pl) * | 2006-12-29 | 2023-01-09 | Ossifi-Mab Llc | Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise |
| WO2008156712A1 (en) * | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| WO2010131185A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
-
2008
- 2008-11-21 EA EA201000844A patent/EA201000844A1/ru unknown
- 2008-11-21 KR KR1020107013609A patent/KR20100099193A/ko not_active Withdrawn
- 2008-11-21 EP EP08855691A patent/EP2220118A2/en not_active Withdrawn
- 2008-11-21 CN CN2008801252375A patent/CN101925611A/zh active Pending
- 2008-11-21 WO PCT/US2008/012987 patent/WO2009070243A2/en not_active Ceased
- 2008-11-21 CA CA2705879A patent/CA2705879A1/en not_active Abandoned
- 2008-11-21 AU AU2008330125A patent/AU2008330125B2/en not_active Ceased
- 2008-11-21 JP JP2010534969A patent/JP5583591B2/ja not_active Expired - Fee Related
- 2008-11-21 MX MX2010005656A patent/MX2010005656A/es active IP Right Grant
- 2008-11-21 US US12/275,850 patent/US8043620B2/en not_active Expired - Fee Related
- 2008-11-21 BR BRPI0820387-3A patent/BRPI0820387A2/pt not_active IP Right Cessation
-
2010
- 2010-05-05 IL IL205569A patent/IL205569A0/en unknown
- 2010-05-14 TN TN2010000213A patent/TN2010000213A1/fr unknown
- 2010-05-20 ZA ZA2010/03578A patent/ZA201003578B/en unknown
- 2010-06-15 MA MA32918A patent/MA31918B1/fr unknown
- 2010-06-21 CR CR11523A patent/CR11523A/es not_active Application Discontinuation
- 2010-06-23 CO CO10075718A patent/CO6311002A2/es not_active Application Discontinuation
-
2011
- 2011-09-15 US US13/233,983 patent/US8309092B2/en active Active
-
2014
- 2014-03-25 JP JP2014061293A patent/JP2014167002A/ja not_active Withdrawn